Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Five Prime Achieves $25M BMS Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Five Prime Achieves $25M BMS Milestone

Initiates Phase II trial evaluating cabiralizumab and Opdivo in advanced pancreatic cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Five Prime Therapeutics achieved a development milestone for cabiralizumab under the license and collaboration agreement with Bristol-Myers Squibb, triggering a $25 million payment. The milestone was triggered by initiation of a Phase II trial sponsored by BMS, evaluating cabiralizumab and Opdivo (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer.

The Phase II trial is expected to enroll approximately 160 patients with locally advanced or metastatic pancreatic cancer that has progressed during or after one line of chemotherapy. 

“Effective treatment for patients with pancreatic cancer remains a significant unmet need and is a cancer for which existing immunotherapies have not been successful to date,” said Helen Collins, M.D., senior vice president and chief medical officer of Five Prime. “We are encouraged by the preliminary data presented at SITC 2017 and are pleased to see this trial underway.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics